Dogma Therapeutics
Dogma is developing oral PCSK9 inhibitors to treat high cholesterol and cardiovascular disease. https://www.dogmatherapeutics.com/
Business Model:
Revenue: $0
Employees: 1-10
Rankings
Industries / Tags:
Detailed Dogma Therapeutics Information
Geographic Data
Address:
City: Boxford
State: Massachusetts
Zip:
Country: United States
Financial Info
Stage:
series a
Raised Last:
$4M
Raised Total:$4M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
The pharmaceutical industry has struggled to identify small molecule inhibitors of PCSK9 function. This has been explained by the expansive but flat binding interface between PCSK9 and the LDL receptor, spanning nearly 800 square angstroms. To date, only monoclonal antibodies have been able to target this region of PCSK9. We have discovered bona fide small molecule inhibitors of PCSK9 function that are orally bioavailable across multiple preclinical species. Guided by dozens of high-resolution x-ray structures of our molecules bound to PCSK9, we have utilized structure-based design to achieve picomolar affinity.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 4/2017 | Series A | 3 | $3.5M |
JMCR Partners Viva BioInnovator Viva Ventures Biotech Fund JMCR Partners Viva BioInnovator Viva Ventures Biotech Fund |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
